You are here

ALX Oncology

ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial

Clinical Trials Arena

Thu, 08/1/24 - 11:12 am

clinical trials

gastroesophageal cancer

ALX follows Gilead in axing CD47 blood cancer trials as data disappoint

Fierce Biotech

Fri, 08/11/23 - 10:09 am

Gilead Sciences

clinical trials

Unpartnered assets: on the shelf or hidden treasure?

EP Vantage

Thu, 06/15/23 - 09:54 am

Ascendis Pharma

Karuna Therapeutics

Madrigal Pharmaceuticals

Protagonist Therapeutics

Ultragenyx Pharmaceutical

Ventyx Biosciences

ALX and Sanofi partner to start Phase l/ll trial of RRMM combo therapy

Clinical Trials Arena

Wed, 04/26/23 - 10:26 am

clinical trials

relapsed or refractory multiple myeloma

Ash 2021 preview – small increases and big falls

EP Vantage

Mon, 11/8/21 - 10:50 am

Global Blood Therapeutics

IGM Biosciences

Five Collaborations Unlocking Faster Drug Development this Week

BioSpace

Thu, 06/10/21 - 11:12 am

drug development

pulmonary fibrosis

Oyster Point Pharma

Adaptive Phage Therapeutics

clinical trials

Shoreline Biosciences

ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study

BioSpace

Tue, 09/22/20 - 12:06 pm

head and neck cancer

Three more biotechs tumble onto Wall Street today, raising $475M as the IPO party rocks on

Endpoints

Fri, 07/17/20 - 10:52 am

Berkeley Lights

Pandion Therapeutics

The biotech IPO boom is becoming ‘historic’ as four more throw their hats in

Endpoints

Mon, 06/29/20 - 10:34 am

Berkeley Lights

Pandion Therapeutics

Kiromic Biopharma

After $105M funding round, ALX Oncology nabs FDA fast-track tag for cancer hopeful

Fierce Biotech

Tue, 02/18/20 - 10:55 am

head and neck cancer

ALX raises $105M for midphase trials of CD47 cancer drug

Fierce Biotech

Wed, 02/12/20 - 10:31 am